Bioequivalence and Bio availability

Bioavailability can be referred to as the rate and extent to which active ingredient or active element of the drug product is absorbed and becomes available at the site of action. The extent and rate of drug absorption are usually measured by the area under the blood or plasma concentration-time curve  (AUC) and the maximum concentration (C max), respectively. 

Bioequivalence: When two drug products or two formulations of the same drug provide the same therapeutic effect, they are said to be bioequivalent, or, that they are therapeutically equivalent. It means, their rates and extent of absorptions do not reflect a significant difference at the site of action.


    Related Conference of Bioequivalence and Bio availability

    February 04-05, 2026

    18th International Conference on Gynecology

    Rome, Italy
    February 25-26, 2026

    15th International Conference on Herbal Medicine and Acupuncture

    Aix-en-Provence, France
    March 09-10, 2026

    13th World Machine Learning and Deep learning Conference

    Singapore City, Singapore
    March 24-25, 2026

    9th Global Congress on Spine and Spinal Disorders

    Paris, France
    March 26-27, 2026

    12th World Congress on Anesthesia and Critical Care

    Amsterdam, Netherlands
    April 20-21, 2026

    47th International Summit on Human Anatomy & Physiology

    Barcelona, Spain
    April 27-28, 2026

    40th International Conference on Psychiatry and Mental Health

    Amsterdam, Netherlands
    April 27-28, 2026

    37th World Congress on Neurorehabilitation

    Dubai, UAE
    May 25-26, 2026

    18th International Conference on Clinical Chemistry

    Zurich, Switzerland
    September 14-15, 2026

    6th World Medicine Congress

    Rome, Italy
    October 19-20, 2026

    12th World Congress on Medicinal Plants and Marine Drugs

    Aix-en-Provence, France

    Bioequivalence and Bio availability Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in